eMedicine from WebMD
eMedicine Home
Developed under the direction and sponsorship of Shire US, Inc. Contains promotional material.

From the Maker of Adderall XR, Introducing Vyvanse- The First Prodrug Stimulant Medication for the Treatment of ADHD

<< Infosite Home

Vyvanse Belongs to a New Class of ADHD Medications

Vyvanse is a long-acting prodrug stimulant


Vyvanse - a new class of ADHD medications
*Vyvanse (lisdexamfetamine dimesylate) is recognized as a new chemical entity


Adderall® is a registered trademark of Shire LLC, under license to Duramed Pharmaceuticals, Inc.
Adderall XR® is a registered trademark of Shire LLC
Concerta® is a registered trademark of ALZA Corporation
Daytrana™ is a trademark of Shire Pharmaceuticals Ireland Ltd
Focalin® and Focalin® XR are trademarks of Novartis Pharmaceuticals Corp
Metadate CD™ is a trademark of UCB, Inc
Ritalin® and Ritalin® LA are registered trademarks of Novartis Pharmaceuticals Corp
Strattera® is a registered trademark of Eli Lilly and Company


Next Section:  How Do Long-Acting Prodrug Stimulants Work?  >>

IMPORTANT SAFETY INFORMATION

Vyvanse should not be taken by patients who have advanced arteriosclerosis; symptomatic cardiovascular disease; moderate to severe hypertension; hyperthyroidism; known hypersensitivity or idiosyncrasy to sympathomimetic amines; agitated states; glaucoma; a history of drug abuse; or during or within 14 days after treatment with monoamine oxidase inhibitors (MAOIs).

Sudden death has been reported in association with CNS stimulant treatment at usual doses in children and adolescents with structural cardiac abnormalities or other serious heart problems. Sudden deaths, stroke, and myocardial infarction have been reported in adults taking stimulant drugs at usual doses in ADHD. Physicians should take a careful patient history, including family history, and physical exam, to assess the presence of cardiac disease. Patients who report symptoms of cardiac disease such as exertional chest pain and unexplained syncope should be promptly evaluated. Use with caution in patients whose underlying medical condition might be affected by increases in blood pressure or heart rate.

New psychosis, mania, aggression, growth suppression, and visual disturbances have been associated with the use of stimulants. Use with caution in patients with a history of psychosis, seizures or EEG abnormalities, bipolar disorder, or depression. Growth monitoring is advised during prolonged treatment.

Amphetamines have a high potential for abuse. Administration of amphetamines for prolonged periods of time may lead to drug dependence. Particular attention should be paid to the possibility of subjects obtaining amphetamines for non-therapeutic uses or distribution to others and the drugs should be prescribed or dispensed sparingly. Misuse of amphetamine may cause sudden death and serious cardiovascular adverse events.

The most common adverse events reported in clinical studies of Vyvanse were loss of appetite, insomnia, abdominal pain, and irritability.